Exclusive Vidalista 40 mg was initially introduced in three standard doses of 20 mg, 40 milligram and 80 mg.
Across all studies with any Vidalista dose, reports of changes in color vision were rare (<0.1% of patients). Therefore, patients who experience anginal chest pain after taking Vidalista should seek immediate medical attention. In those patients who are stable on alpha-blocker therapy, PDE5 inhibitors should be initiated at the lowest recommended dose. In patients with creatinine clearance 30 - 50 mL/min, start dosing at 2.5 mg once daily, and increase the dose to 5 mg once daily based upon individual response see DOSAGE AND ADMINISTRATION , Use In Specific Populations, and CLINICAL PHARMACOLOGY.
Patients should be made aware that both alcohol and Vidalista, a PDE5 inhibitor, act as mild vasodilators. Inform patients not to take Vidalista with other PDE5 inhibitors, including ADCIRCA. Physicians should discuss with patients the contraindication of Vidalista with regular and/or intermittent use of organic nitrates.
Physicians should discuss with patients the potential for Vidalista to augment the blood-pressure-lowering effect of alpha-blockers, and antihypertensive medications see WARNINGS AND PRECAUTIONS, DRUG INTERACTIONS , and CLINICAL PHARMACOLOGY. Therefore, physicians should inform patients that substantial consumption of alcohol (e.g., 5 units or greater) in combination with Vidalista can increase the potential for orthostatic signs and symptoms, including increase in heart rate, decrease in standing blood pressure, dizziness, and headache see WARNINGS AND PRECAUTIONS, DRUG INTERACTIONS , and CLINICAL PHARMACOLOGY. For Vidalista for use as needed in men with ED, patients should be instructed to take one tablet at least 30 minutes before anticipated sexual activity.
Vidalista is effective at improving erectile function over the course of therapy. Tadalafil was not carcinogenic to rats or mice when administered daily for 2 years at doses up to 400 mg/kg/day. There were no effects on fertility, reproductive performance or reproductive organ morphology in male or female rats given oral doses of tadalafil up to 400 mg/kg/day, a dose producing AUCs for unbound tadalafil of 14-fold for males or 26-fold for females the exposures observed in human males given the MRHD of 20 mg. In beagle dogs given tadalafil daily for 3 to 12 months, there was treatment-related non-reversible degeneration and atrophy of the seminiferous tubular epithelium in the testes in 20-100% of the dogs that resulted in a decrease in spermatogenesis in 40-75% of the dogs at doses of ?10 mg/kg/day.
Vidalista (tadalafil) is not indicated for use in women. In one of two perinatal /postnatal developmental studies in rats, postnatal pup survival decreased following maternal exposure to tadalafil doses greater than 10 times the MRHD based on AUC. Vidalista is not indicated for use in pediatric patients - https://vidalista.biz/
In clinical pharmacology studies, tadalafil exposure (AUC) in subjects with mild or moderate hepatic impairment (Child-Pugh Class A or B) was comparable to exposure in healthy subjects when a dose of 10 mg was administered.
To learn more about evidalista.com/es website: check here.